[Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to ยง 35a Social Code Book V (dossier assessment)]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002911
Original Title: Addendum zum Auftrag A12-02 (Rilpivirin/Emtricitabin/Tenofovir)
Project Status: Completed
Year Published: 2012
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • HIV
  • HIV Infections
  • Emtricitabine, Rilpivirine, Tenofovir Drug Combination
  • Rilpivirine
  • Emtricitabine
  • Tenofovir
  • Drug Therapy, Combination
  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Rilpivirine
  • Emtricitabine
  • Tenofovir Disoproxil
  • Human Immunodeficiency Virus Type 1
  • Benefit Assessment
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.